Lord Abbett & CO. LLC Buys 526,732 Shares of Danaher Corporation $DHR

Lord Abbett & CO. LLC lifted its stake in shares of Danaher Corporation (NYSE:DHR) by 307.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 698,256 shares of the conglomerate’s stock after purchasing an additional 526,732 shares during the quarter. Lord Abbett & CO. LLC owned 0.10% of Danaher worth $159,845,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. Sivia Capital Partners LLC raised its stake in shares of Danaher by 6.3% during the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after purchasing an additional 119 shares during the period. First Trust Advisors LP raised its stake in shares of Danaher by 34.5% during the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after purchasing an additional 14,217 shares during the period. Main Street Financial Solutions LLC raised its stake in shares of Danaher by 40.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after purchasing an additional 886 shares during the period. Ieq Capital LLC raised its stake in shares of Danaher by 64.2% during the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after purchasing an additional 29,592 shares during the period. Finally, HUB Investment Partners LLC raised its stake in shares of Danaher by 30.7% during the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock valued at $273,000 after purchasing an additional 325 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of NYSE DHR opened at $179.95 on Friday. The firm has a market capitalization of $127.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.41 and a beta of 0.81. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The stock’s 50-day simple moving average is $180.93 and its two-hundred day simple moving average is $204.78. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.88 EPS. As a group, equities analysts anticipate that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio is 30.95%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. The Goldman Sachs Group decreased their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Wells Fargo & Company decreased their price objective on Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 22nd. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Barclays decreased their target price on Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Finally, Guggenheim decreased their target price on Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $233.61.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.